Retatrutide
Retatrutide
The bleeding-edge of weight-loss medication. Known as a "triple-G" agonist, it targets GLP-1, GIP, and Glucagon receptors simultaneously. Currently in late-stage clinical trials, it is showing unprecedented weight loss results that rival bariatric surgery.
Evidence Level 路 3/5 路 Restricted
Strong animal and lab research
01
Extreme Weight Loss
Phase 2 trials showed an average weight loss of 24% after 48 weeks at higher doses, surpassing both Semaglutide and Tirzepatide in sheer efficacy.
02
Metabolic Optimization
The addition of the Glucagon receptor actively increases basal metabolic rate and energy expenditure, rather than just suppressing appetite.
03
Liver Fat Reduction
Studied for aggressively resolving non-alcoholic fatty liver disease (NAFLD) with rapid liver fat clearance.
Not medical advice. Talk to a licensed provider.